Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial
Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial
复制标题
DOI：
10.1111/ajt.14520
复制
发表时间：
2018-04-01
影响因子：
8.8
通讯作者：
Seron, Daniel
中科院分区：
文献类型：
--
作者：
Moreso, Francesc;Crespo, Marta;Seron, Daniel
目前尚无获批的慢性抗体介导的排斥反应（ABMR）治疗方法。我们进行了一项多中心、前瞻性、随机、安慰剂对照、双盲临床试验，以评价静脉注射免疫球蛋白（IVIG）联合利妥昔单抗（RTX）的疗效和安全性（EudraCT 2010-023746-67）。有移植肾小球病和抗HLA供体特异性抗体（DSA）的患者符合条件。估计肾小球滤过率（eGFR）的患者
There are no approved treatments for chronic antibody mediated rejection (ABMR). We conducted a multicenter, prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate efficacy and safety of intravenous immunoglobulins (IVIG) combined with rituximab (RTX) (EudraCT 2010-023746-67). Patients with transplant glomerulopathy and anti-HLA donor-specific antibodies (DSA) were eligible. Patients with estimated glomerular filtration rate (eGFR)